Drug Database
ME

measles vaccine (live-attenuated)

✓ Approved

Beijing Tiantan Biological Products · Vaccine · Vaccine

What is measles vaccine (live-attenuated)?

measles vaccine (live-attenuated) is a vaccine developed by Beijing Tiantan Biological Products. It is approved for therapeutic indications via unknown.

Drug Profile

CompanyBeijing Tiantan Biological Products
Drug ClassVaccine, Large Molecules
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Beijing Tiantan Biological Products

Therapeutic Indications

measles vaccine (live-attenuated) is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsMeasles✓ Approved

Related Research Articles

PubMedVaccine2026-07-25

Characterization of vaccine viremia, attenuation reversion, and safety: Combined results from the TAK-003 dengue vaccine clinical development program.

Tricou Vianney V, Saez-Llorens Xavier X, Kosalaraksa Pope P, Reynales Humberto H et al.

Live-attenuated vaccines can replicate for a transient period post-vaccination and may be associated with symptoms resembling natural infection. The tetravalent dengue vaccine, TAK-003, has undergone extensive preclinical assessment to investigate vaccine RNAemia, viremia, genetic stability, and transmissibility. Here, we investigated the presence of vaccine RNAemia, attenuation loci reversions, and their association with viral-syndrome-like adverse events (AEs) in participants throughout the clinical development program. TAK-003 RNA positive serum samples were evaluated for viral replication and sequenced for reversions. Safety data (solicited AEs within 7/14 days; unsolicited AEs within 28 days) were assessed from a pooled phase 1/2 trial analysis. Participants who experienced febrile illness within 30 days post vaccination in the pivotal phase 3 DEN-301 trial and the phase 2 DEN-313 trial were tested for RNAemia and evaluated for AEs. TAK-003 RNAemia was detected in 441/805 (54.8%) of vaccinees (seronegative: 67.0%; seropositive: 33.0%) in the pooled analysis and in 39 participants with febrile illness from the DEN-301/DEN-313 trials (from 1022 febrile illnesses investigated). RNAemia peaked during the second week post-vaccination and mostly occurred after first dose. Although all four dengue virus (DENV) components were detected, RNAemia was most commonly due to DENV-2. 69 single locus reversions were detected; AEs reported in participants with reversions were generally non-serious, and not indicative of increased symptom severity. Pain at injection site (without RNAemia = 42.0%; RNAemia = 46.8%) and headache (without RNAemia = 36.6%; RNAemia = 37.6%) were the most frequently reported solicited AEs. Incidences of pain, erythema, rash, arthralgia, and fatigue were higher in participants with RNAemia. The incidence of unsolicited AEs was higher in participants with RNAemia (62.4%) than without (52.0%). In the DEN-301/DEN-313 analysis, participants with febrile illness showed a similar pattern of symptoms with and without RNAemia. The presence of RNAemia was associated with transient, mild-to-moderate symptoms, resembling natural infection, which were also observed in the absence of RNAemia.

PMID 42497670
Read full article →
PubMedResearch in veterinary science2026-07-25

An intervention study to compare the outcome of administering a live intranasal Bovine Respiratory Syncytial Virus and Parainfluenza-3 vaccine to maternally derived antibody positive calves on the day of birth with calves vaccinated at one week of age.

Baxter-Smith Katharine K, Baird Graham G, Cooper Richard R, Roberts Jude J et al.

The aim of the study was to demonstrate the efficacy of Bovilis INtranasal RSP Live administered on the day of birth (DoB) compared with administering the same vaccine between seven and ten days of age (D7). Health (including antibiotic treatments), mortality outcomes and weights in two groups of calves (DoB and D7) were monitored. Calves (n = 847) from seven farms were administered the vaccine on DoB or between day 7 and day 10 (D7) of life. Animals were weighed at week 1, weeks 3-4 and week 8 of life, using weigh tapes. Average daily liveweight gains (DLWG) were calculated. Adverse health events, treatments and mortality were recorded by farmers. Overall mean growth rate was 0.64 kg/day in the first eight weeks of life, with high intra-farm variability in DLWG (0.31-0.81 kg/day). Mixed linear and Poisson models (with farm as a random effect) revealed no statistically significant effect of vaccination timing on any of the outcomes of interest. Animals were kept in the same environment, such that cross-protection from vaccination in the DoB group could have decreased the true effect size of differing vaccination protocols. Results suggest that Bovilis INtranasal vaccination may be administered on DoB or D7 equivalently, depending on respiratory disease risk and farmer and veterinarian preference.

PMID 42497673
Read full article →
PubMedNature microbiology2026-07-25

Antiviral GHP-88310 blocks contact-mediated and airborne transmission in a ferret model of measles-like disease.

Lieber Carolin M CM, Wolf Josef D JD, Ruckel Claire E CE, Harrison Lauren A LA et al.

The 2025/2026 measles resurgence in North America highlighted that antivirals may be valuable in protecting child health because of mounting vaccination hesitancy. The drug candidate GHP-88310 is an orally efficacious broad-spectrum orthoparamyxovirus polymerase inhibitor, but its effect on viral transmission is unclear. Here we used canine distemper virus, which causes measles-like disease in ferrets, and established direct-contact and airborne canine distemper virus transmission models to examine pharmacological suppression of virus spread. Prophylactic GHP-88310 administration alleviated clinical signs of direct contacts and all sentinels survived. Pre- and post-exposure prophylactic GHP-88310 given twice daily to air contacts prevented transmission. Once-daily prophylactic administration mediated complete survival with all air contacts undergoing seroconversion. Therapeutic treatment of air contacts mitigated clinical signs, and animals survived, whereas all vehicle-treated air contacts succumbed. Therapeutic treatment of infected source animals shortened the contagious phase by 5 days. These results establish conceptual proof that GHP-88310 can suppress social contact transmission. Therapeutic treatment of sources promises epidemiological gain in addition to therapeutic benefit.

PMID 42498819
Read full article →
PubMedJournal of pharmaceutical policy and practice2026-07-25

Cost-utility and budget impact analysis of herpes zoster vaccines in Thai patients with end-stage renal disease.

Kulthanachairojana Nattanichcha N, Phothong Pattheera P, Promkladphanao Pitch P, Singharerg Chollakarn C et al.

Patients with end-stage renal disease (ESRD) are increased risk of herpes zoster (HZ). The economic value of HZ vaccines in Thai patients with ESRD has not been assessed. This study evaluated the cost-utility and budget impact of two HZ vaccination strategies - zoster vaccine live (ZVL) and recombinant zoster vaccine (RZV) - compared with no vaccination in Thailand. A Markov model was developed to estimate lifetime health and economic outcomes in patients with ESRD. Cost-utility analysis was conducted from a societal perspective, while budget impact analysis was performed from a payer perspective over a 5-year time horizon. Model inputs were derived from published literature and Thai data sources. Uncertainty was assessed using deterministic, probabilistic, and scenario sensitivity analyses. In the base-case analysis, both ZVL and RZV were cost-effective compared with no vaccination, with incremental cost-effectiveness ratios (ICER) of USD 1,599.14 (THB 51,912.56) and USD 2,920.09 (THB 94,794.30) per quality-adjusted life year (QALY) gained, respectively - both below Thailand's willingness-to-pay threshold. RZV generated greater health benefits but was associated with higher costs. Sensitivity analyses confirmed the robustness of cost-effectiveness results across key assumptions. Over a 5-year period, the estimated budget impact ranged from USD 4.99-9.55 million (THB 161.86-310.02 million) for ZVL and USD 28.92-55.42 million (THB 938.95-1,799.09 million) for RZV, depending on vaccine uptake assumptions, with expenditures largely concentrated in the first year due to vaccination of prevalent patients. Both HZ vaccines are cost-effective options for preventing HZ in Thai patients with ESRD. While RZV provides greater health gains, it requires substantially higher budgetary investment. These findings support prioritising HZ vaccination for patients with ESRD and initiating pilot implementation within dialysis care settings to assess system-level impact and feasibility.

PMID 42499779
Read full article →
PubMedFrontiers in immunology2026-07-25

Translating viral genetic data to PRRSV-2 cross-neutralization using machine learning.

Pamornchainavakul Nakarin N, Huang Jing J, Paploski Igor A D IAD, Makau Dennis N DN et al.

Swine herd immunization through modified live vaccination or live virus inoculation is a core strategy for controlling porcine reproductive and respiratory syndrome (PRRS), one of the most economically important endemic diseases in the United States that is caused by PRRSV-2. While antigenically homologous PRRSV-2 viruses are expected to elicit better immunological cross-protection, questions remain as to how genetic similarity translates to the degree of cross-protection elicited between the immunizing strain and subsequent challenge virus. For PRRSV-2, virus neutralization (VN) assays are commonly used to approximate humoral immune responses and to assess cross-variant vaccine efficacy; however, these assays are labor-intensive and difficult to scale for rapid immunization planning. Here, we developed a machine learning-based predictive model for PRRSV-2 cross-neutralization using viral genetic sequence data to address this gap. Virus neutralization assays were performed across a panel of viral isolates and anti-sera, representing a variety of contemporary and vaccine-like PRRSV-2 variants. Our internal dataset comprised 219 cross-neutralization pairs involving nine viral isolates and 25 antisera generated from animals inoculated with six isolates (immunizing viruses). Neutralization titers were classified as above versus below average using mean standardized log2 titers as the cutoff. Candidate predictors included residue-wise amino acid property differences, overall viral genetic distances, and protein structural comparison metrics. Eleven machine learning algorithms were trained and evaluated using internal and external test sets. The best models, which utilized predictors from protein ectodomain features, effectively estimated whether a virus-antisera pair would exhibit above versus below average neutralization, achieving balanced accuracies of 87-92% on internal data, and 71-89% across three external VN datasets. Key predictors included amino acid properties in GP5 decoy epitope and hypervariable regions, residues within GP2-GP3 epitopes, and overall genetic distance. These models are publicly available through a web-based tool (https://stemma.shinyapps.io/PRRSLoom-NeutralizationPredictor/) for end-users to estimate the neutralization potential between genetically distinct PRRSV-2 viruses. Our integration of machine learning, in vitro experimental data, and webtool bridges experimental research with real-world application in veterinary decision-making.

PMID 42500660
Read full article →
PubMedJournal of the International AIDS Society2026-07-25

Behavioural and Structural Determinants of Mpox Vaccine Awareness and Uptake Among People With HIV in the Dominican Republic: A Cross-Sectional Study.

Paulino-Ramirez Robert R, Matias Wilfredo R WR, Chaumette Alexandre A, Lora-Rodríguez Hector H et al.

Mpox disproportionately affects people with HIV (PWH), yet little is known about mpox vaccine awareness and uptake in low- and middle-income countries. We evaluated mpox-related knowledge, attitudes and practices (KAP) among PWH in the Dominican Republic to identify determinants of vaccine awareness and uptake. We conducted a cross-sectional online survey of 98 PWH recruited through HIV clinics, community-based organizations and social networks (January-May 2025). The questionnaire assessed sociodemographic characteristics, mpox-related KAP, structural barriers and vaccination status. Univariable and multivariable logistic regression were used to examine factors associated with mpox vaccine awareness. Half of the participants (49/98) were aware of the mpox vaccine. Individuals aged 31-40 years had significantly lower odds of awareness compared with those aged 21-30 years. Despite high levels of formal education, 79% rated their mpox knowledge as low, and most perceived minimal personal risk. Among participants aware of the vaccine, 71% had been vaccinated. Structural barriers, including inconvenient site locations and logistical challenges, were frequently reported, even among vaccinated individuals, indicating that access limitations rather than hesitancy were the dominant constraints. Trust in vaccinating organizations was high overall, and healthcare providers and community organizations were the primary sources of vaccine information. Peer and community influence emerged as notable facilitators of uptake, while lack of reliable information and concerns about vaccine safety contributed to hesitancy. Mpox vaccine awareness among PWH in the Dominican Republic was low, but willingness to vaccinate was high when individuals were informed and able to access services. Strengthening mpox preparedness will require expanding accessible vaccination sites, improving disease-specific health literacy, and leveraging trusted community and clinical networks. Integrating mpox vaccination into routine HIV care delivery and enhancing community-led outreach may substantially improve uptake in this and similar low-middle income countries (LMIC) settings.

PMID 42499164
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about measles vaccine (live-attenuated)